Neteera Technologies vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 36)
Neteera Technologies logo

Neteera Technologies

EmergingHealthcare

Contactless Remote Patient Monitoring

Israeli healthtech with FDA-cleared and CE-certified contactless RPM system that captures vital signs without sensors touching the patient; $6.7M Series B; 11–50 employees; active clinical deployments.

AI VisibilityBeta
Overall Score
D36
Category Rank
#529 of 596
AI Consensus
74%
Trend
stable
Per Platform
ChatGPT
31
Perplexity
39
Gemini
30

About

Neteera Technologies is an Israeli digital health company developing contactless remote patient monitoring (RPM) solutions that capture vital signs and behavioral parameters without any physical contact with the patient. Founded and headquartered in Israel, Neteera's technology uses proprietary radar-based sensing to measure respiration rate, heart rate, body movement, and other physiological signals through a bedside device — no wearables, electrodes, or patient cooperation required. This contactless approach is particularly valuable for patients who cannot tolerate wearable sensors (elderly, agitated, or critically ill patients) and for settings requiring continuous monitoring without nursing staff intervention.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

36
Overall Score
93
#529
Category Rank
#1
74
AI Consensus
80
stable
Trend
stable
31
ChatGPT
94
39
Perplexity
89
30
Gemini
94
38
Claude
92
31
Grok
98

Key Details

Category
Contactless Remote Patient Monitoring
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.